Optical Genome Mapping Market Report 2026

The optical genome mapping market size has grown exponentially in recent years. It will grow from $0.23 billion in 2025 to $0.29 billion in 2026 at a compound annual growth rate (CAGR) of 29.4%. The growth in the historic period can be attributed to limitations of next generation sequencing in detecting large structural variants, increasing genomic research funding, rising prevalence of genetic disorders, growing demand for advanced cytogenetic techniques, technological advancements in imaging and DNA labeling.

The optical genome mapping market size is expected to see exponential growth in the next few years. It will grow to $0.74 billion in 2030 at a compound annual growth rate (CAGR) of 25.9%. The growth in the forecast period can be attributed to increasing integration of ogm in clinical laboratories, rising investment in precision medicine initiatives, growing adoption of automated genomic analysis platforms, expanding applications in oncology and hematological malignancies, declining costs of genomic analysis technologies. Major trends in the forecast period include growing adoption of optical genome mapping in structural variant detection, increasing use of ogm in rare disease and cancer research, rising demand for high-resolution long-read genomic analysis, expansion of ogm applications in clinical diagnostics, growing preference for complementary use of ogm with sequencing technologies.

The growing demand for precision medicine is expected to drive growth in the optical genome mapping (OGM) market in the coming years. Precision medicine tailors medical treatment and prevention strategies to individual characteristics, including genetic makeup, lifestyle, and environment. This demand is fueled by the rising prevalence of chronic diseases, advancements in genomic technologies, increased investment and funding, and patient interest in personalized care. Optical genome mapping enhances precision medicine by providing detailed, accurate insights into genomic alterations associated with various diseases. For example, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit, the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, compared with six approvals in 2022. The increasing adoption of precision medicine is therefore propelling the OGM market.

Key companies in the OGM market are focusing on technological innovations, such as OGM-based laboratory-developed tests (LDTs), for comprehensive genome-wide structural variant detection. These tests enhance diagnostic accuracy, streamline workflows, and reduce reliance on multiple traditional cytogenetic assays. An OGM-based LDT uses ultra-long, high-molecular-weight DNA molecules that are fluorescently labeled and linearized in nanochannels, enabling high-resolution imaging to detect insertions, deletions, translocations, and repeat expansions - variants often missed by short-read sequencing or microarrays. For instance, in March 2023, Bionano Laboratories, a U.S.-based CLIA-certified subsidiary of Bionano Genomics, launched the OGM Dx Postnatal Whole Genome SV test. This test allows genome-wide detection of structural variants in patients with developmental disorders, intellectual disabilities, autism spectrum disorder, epilepsy, or undiagnosed genetic conditions, integrating high-resolution OGM with variant calling in a single workflow to reduce the need for multiple classical cytogenetic tests and provide faster, more comprehensive diagnostic insights.

In June 2024, Bionano Genomics, a U.S.-based provider of OGM systems, consumables, and software, partnered with Revvity to integrate Bionano’s VIA software into Revvity’s newborn sequencing research workflow. This collaboration aims to combine OGM data with next-generation sequencing (NGS) workflows to enhance comprehensive variant analysis and improve structural variant detection. The partnership underscores the OGM market’s increasing focus on software-enabled integration with broader genomics research platforms. Revvity is a U.S.-based provider of genomics research solutions.

Major companies operating in the optical genome mapping market are Bionano Genomics Inc., 10x Genomics Inc., Oxford Nanopore Technologies plc, Pacific Biosciences of California Inc., BioSkryb Genomics, Phase Genomics Inc., Nabsys, Daicel Arbor Biosciences, OpGen, Thermo Fisher Scientific Inc., Roche Sequencing Solutions, Genomic Vision SA, INRAE French Plant Genomic Resources Center, Source BioScience, Resolve Biosciences, Arima Genomics Inc., GnuBIO Inc., Longas Technologies, GE Healthcare Life Sciences, Danaher Corporation, Strand Life Sciences, Berry Genomics, Dante Genomics.

North America was the largest region in the optical genome mapping market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the optical genome mapping market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the optical genome mapping market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the optical genome mapping market by increasing costs of imported imaging systems, optical components, and specialized reagents used in OGM workflows. Biotechnology and pharmaceutical companies along with clinical laboratories in north america, europe, and asia-pacific are most affected due to dependence on globally sourced instruments and consumables. However, tariffs are also encouraging localized manufacturing, regional supply chain development, and domestic production of genomic instruments, which may strengthen long-term market resilience and innovation.

The optical genome mapping market research report is one of a series of new reports that provides optical genome mapping market statistics, including optical genome mapping industry global market size, regional shares, competitors with a optical genome mapping market share, detailed optical genome mapping market segments, market trends and opportunities, and any further data you may need to thrive in the optical genome mapping industry. This optical genome mapping market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Optical genome mapping (OGM) is an advanced genomic analysis technique that creates high-resolution, large-scale maps of DNA molecules to identify structural variations and genome architecture. This technology uses optical methods to visualize and analyze long DNA strands, enabling the detection of large-scale structural variations - such as insertions, deletions, duplications, inversions, and translocations - that are often difficult to identify with traditional sequencing methods.

The main products in the optical genome mapping market include instruments, consumables and reagents, software, and services. Instruments encompass the hardware and machinery used to visualize and analyze large DNA molecules. OGM is applied in areas such as structural variant detection, genome assembly, microbial strain typing, and other applications, and is utilized by biotechnology and pharmaceutical companies, clinical laboratories, academic research institutes, and other end users.

The optical genome mapping market includes revenues earned by entities by providing services such as structural variation detection, genome assembly, microbial strain typing, clinical diagnostics, cancer genomics bioinformatics, and data analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The optical genome mapping market also includes sales of instruments, consumables and reagents, software, and bioinformatics tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.